XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Operating expenses    
Research and development $ 2,745 $ 1,157
General and administrative 2,575 542
Total operating expenses 5,320 1,699
Financing expenses (income), net (216) 5
Net loss for the period $ 5,104 $ 1,704
Basic and diluted loss per Ordinary Share [1] $ 0.022 $ 0.011
Weighted average number of Ordinary Shares outstanding, basic, and diluted [1] 228,090,300 156,751,771
[1] Number of shares has been retroactively adjusted based on the equivalent number of shares received by the accounting acquirer’s shareholders in the reverse recapitalization transaction (refer to Note 1B).